comparemela.com

Latest Breaking News On - Kidney cancer program - Page 3 : comparemela.com

'Breakthrough': Adjuvant Pembro Ups Survival in Renal Cancer

KEYNOTE-564 is the first trial to demonstrate an overall survival benefit with adjuvant immunotherapy in patients with clear cell renal cell carcinoma.

United-states
Massachusetts
Cleveland
Ohio
Dana-farber-cancer-institute
Boston
American
Pedroc-barata
Tonik-choueiri
Kidney-cancer-program-at-dana-farber-institute
American-society-of-clinical-oncology-genitourinary-symposium

Postsurgical Keytruda Boosts Survival in Clear Cell Renal Cell Carcinoma

Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo.

Boston
Massachusetts
United-states
Dana-farber-cancer-institute
Nancy-kohlberg
Toni-choueiri
Kidney-cancer-program
Lank-center
Harvard-medical-school
Genitourinary-oncology
Nancy-kohlberg-chair
Enrollment-criteria

Adjuvant Pembrolizumab Significantly Prolongs OS vs Placebo in ccRCC

Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

Massachusetts
United-states
Boston
Dana-farber-cancer-institute
Bristol-myers-squibb
Nancy-kohlberg
Toni-choueiri
Roche-genentech
Calithera-biosciences
Sanofi-aventis
Astrazeneca
Michaelj-hennessy-associates

Dr Pal on the Rationale for Investigating Zanzalintinib in Relapsed/Refractory ccRCC

Sumanta Kumar Pal, MD, FASCO, chair, discusses the rationale for treating patients with zanzalintinib in relapsed/refractory clear cell renal cell carcinoma.

Sumanta-kumar-pal
Bladder-cancer-disease-team
Department-of-medical-oncology
Kidney-cancer-program
International-kidney-cancer-symposium
Therapeutics-research
Medical-oncology
Kidney-cancer-symposium
City-of-hope
Onclive-tv
Genitourinary-cancers

BLA Submitted to FDA for PET Imaging Agent TLX250-CDx in RCC

A biologics license application seeking the approval of the investigational positron emission tomography imaging agent 89Zr-DFO-girentuximab in clear cell renal cell carcinoma has been submitted to the FDA.

Cdx-zircaix
Brian-shuch
James-stonecypher
Alvin-carrie-meinhardt
Christian-behrenbruch
Institute-of-urologic-oncology
Telix-group
Kidney-cancer-program
Kidney-cancer-research
Cancers-symposium
Carrie-meinhardt-endowed-chair
Urologic-oncology

vimarsana © 2020. All Rights Reserved.